Takeda Pharmaceutical (TAK) Operating Expenses (2017 - 2026)

Takeda Pharmaceutical has reported Operating Expenses for 10 years, with the latest figure at -$2.8 billion in Q2 2026.

• On a quarterly basis, Operating Expenses fell 53.58% year-over-year to -$2.8 billion in Q2 2026; TTM through Jun 2026 was -$12.1 billion, a 9.95% decrease from a year earlier, with the FY2026 full-year figure at -$1.8 billion, down 3.07% from the prior year.
• Operating Expenses was -$2.8 billion for Q2 2026 at Takeda Pharmaceutical, down from -$1.8 billion in the prior quarter.
• The five-year high for Operating Expenses was -$1.7 billion in Q2 2024, with the low at -$5.5 billion in Q3 2025.
• Average Operating Expenses over 5 years is -$2.8 billion, with a median of -$1.9 billion recorded in 2022.
• The largest YoY upside for Operating Expenses was 42.97% in 2022 against a maximum downside of 72.24% in 2022.
• Over 5 years, Operating Expenses stood at -$1.8 billion in 2022, then dropped by 6.98% to -$1.9 billion in 2023, then dropped by 0.88% to -$1.9 billion in 2024, then rose by 1.21% to -$1.9 billion in 2025, then sank by 48.11% to -$2.8 billion in 2026.
• The last three Operating Expenses figures came in at -$2.8 billion (Q2 2026), -$1.8 billion (Q1 2026), and -$1.9 billion (Q4 2025), per Business Quant data.